NeoRx MoAb agent gets FDA panel's nod

Article

A monoclonal antibody imaging agent under development by NeoRxcleared a major hurdle this month when a Food and Drug Administrationadvisory committee recommended the product for approval. The panel'smove puts NeoRx's Verluma, formerly known as OncoTrac,

A monoclonal antibody imaging agent under development by NeoRxcleared a major hurdle this month when a Food and Drug Administrationadvisory committee recommended the product for approval. The panel'smove puts NeoRx's Verluma, formerly known as OncoTrac, into positionto be the second monoclonal antibody-based imaging agent to reachthe market, after Cytogen's OncoScint CR/OV.

The FDA's Oncologic Drugs Advisory Committee recommended thatVerluma's product license application (PLA) be approved for theinitial staging of patients with biopsy-confirmed small-cell lungcancer. NeoRx hopes that Verluma, a technetium-labeled monoclonalantibody fragment, will prove cheaper and more useful than traditionalbatteries of tests for small-cell lung cancer, such as CT andbone scans. NeoRx representatives also say Verluma has a lowerHAMA (human anti-mouse antibody) response rate than other monoclonalantibody agents.

Seattle-based NeoRx has licensed North American rights forVerluma to Du Pont Merck Pharmaceutical (SCAN 10/26/94). BoehringerIngelheim manufactures Verluma for NeoRx.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.